Status:
SUSPENDED
The Effect of CRT on the Hypercapnic Ventilatory Response
Lead Sponsor:
Royal Brompton & Harefield NHS Foundation Trust
Collaborating Sponsors:
Boston Scientific Corporation
Conditions:
Sleep Disordered Breathing
Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
Central Sleep Apnoea (CSA) affects up to half of patients with severe heart failure and is associated with a poor prognosis. CSA is manifest as episodes of deep breathing interspersed with very shallo...
Detailed Description
Sleep disordered Breathing is common in heart failure, affecting around half of patients. This may be Obstructive Sleep Apnoea due to loss of pharyngeal muscle tone (OSA, associated with obesity and s...
Eligibility Criteria
Inclusion
- Heart failure with reduced ejection fraction (\<40%)
- Either no significant sleep disordered breathing or moderate to severe CSA
- Able to consent to the study
- Ambulatory
- Aged 18-100 years
Exclusion
- Patients on Non-Invasive Ventilation
- Predominant OSA
- Unable to consent or attend for the study
Key Trial Info
Start Date :
June 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2017
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT02203383
Start Date
June 1 2014
End Date
October 1 2017
Last Update
November 9 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Brompton and Harefield NHS Foundation Trust
London, United Kingdom, SW6 6NP